Stability Report. Accelerated and long-term testing. with registration batches. BIWG 98 SE drug substance SR
|
|
- Erin Riley
- 5 years ago
- Views:
Transcription
1 Stability Report Accelerated and long-term testing with registration batches BIWG 98 SE drug substance Number SR Date Page of 30 Responsible Company Successful Pharma KG Biberach Responsible: Analytical Sciences Department Drug Product Analysis Laboratory AZ 221
2 BIWG 98 SE drug substance Page 2 of 30 Table of contents Table of contents Summary Structural formula Stability results Proposed Re-test period and container closure system information Commitment: On-going Stability testing 2. Introduction Material and Methods Batch information Manufacture Container closure system Test attributes Analytical procedures Test attributes and Acceptance criteria Stability test protocols Accelerated and long-term testing according to the ICH Guideline Stability Testing of Drug Substances and Products Photostability testing according to the ICH Guideline Photostability Testing of New Drug Substances and Products Results and Evaluation Graphic of test results Test results Evaluation Organoleptical properties: Physico-chemical properties: Chemical properties: Container closure system properties: Photostability: Conclusion Statements...28
3 BIWG 98 SE drug substance Page 3 of Summary 1.1 Structural formula N N CH 3 O OH BIWG 98 SE
4 BIWG 98 SE drug substance Page 4 of Stability results The Stability Report comprises the primary stability data of the three registration batches of BIWG 98 SE drug substance. The samples were stored up to 18 respectively 12 months at 25 C/60 % r.h. and up to 6 months at 40 C/75 % r.h.. No change in organoleptic, physico-chemical, chemical properties took place. Not sensitive to light. No interaction with the packaging material took place. An overview is given in the following table. Batch No. Test attributes Storage conditions [ C] [% r.h.] Storage time [months] Analytical results S96013* Appearance ,3,6,9,12,(18) * no change ,6 no change S96014 Odour ,3,6,9,12,(18) no change ,6 no change S96015 Colour of solution ,3,6,9,12,(18) no change ,6 no change Clarity of solution ,3,6,9,12,(18) no change ,6 no change Melting behaviour ,3,6,9,12,(18) no change ,6 no change Loss on drying ,3,6,9,12,(18) no change ,6 no change Degradation of ,3,6,9,12,(18) no degradation BIWG 98 SE ,6 no degradation Assay of ,3,6,9,12,(18) no fall in assay BIWG 98 SE ,6 no fall in assay * batch No. S months, S96014, S months The data of assay of BIWG 98 SE are also presented graphically The primary Accelerated- and Long-Term Stability test results confirmed fully the data of the Stress Testing with the drug substance, documented in the Stability Report "Active Ingredient Stability Profile of BIWG 98 SE drug substance, No. SSRS dated ". Summarizing the primary and the supportive stability data, it can be concluded: The NME drug substance BIWG 98 SE is stable. It should be stored in a tight container.
5 BIWG 98 SE drug substance Page 5 of Proposed Re-test period and Container closure system information A preliminary re-test period of 24 months is derived from the resulting data. The stability testing will be continued up to 60 months, with the intention of extending the re-test period up to 60 months, if the data adequately support that conclusion. After 60 months the samples are analysed for immediate use. Example: After release re-test period: 60 months After 5 years analysis before immediate use Preliminary Re-test period Container closure system Climatic zone Re-test period Polyethylene bag in stainless steel container II 24 months Storage instructions: According to the results no storage instructions are required, even if the shelf-life will be extended up to 60 months. Nevertheless storage instructions may be necessary due to the national requirements. Countries EU Japan Storage instructions none none USA Store at 25 C, excursion permitted to C
6 BIWG 98 SE drug substance Page 6 of Commitment: On-going Stability testing The stability testing will be continued as On-going Stability Testing according to the ICH Guideline "Stability Testing". Part 1 Continuation of the storage and investigation of the three registration batches up to 60 months. Batches S96013 S96014 S96015 Storage condition Storage period Testing frequency [months] Testing specifications 25 C/60 % r.h. (18), 24, 36, 48, 60 TSS 90-A-01/02 Part 2 After marketing authorisation 3 production batches are put on stability. Batches Storage condition Storage period Testing frequency Testing specifications [months] 3 production batches 25 C/60 % r.h. 0, 6, 12, 18, 24, 36, 60 TSS 90-A-01/02 or equivalent The available data will be submitted annually.
7 BIWG 98 SE drug substance Page 7 of Introduction In this report the primary stability testing is described with the 3 registration batches of the NCE drug substance BIWG 98 SE. The investigations were performed according to the ICH Guideline "Stability Testing of New Drug Substances and Drug Products".
8 BIWG 98 SE drug substance Page 8 of 30 3 Material and Methods 3.1 Batch information Manufacture The three registration batches have been manufactured in pilot plant scale by the same synthetic route and use a method of manufacture and procedure that simulates the final process to be used on a manufacturing scale. Batch No. S96013 S96014 S96015 Manufacturer Successful Pharma KG Biberach Date of manufacture Aug Sept Nov Site of manufacture Scale of manufacture Pilot Plant Pilot Scale Batch size 100 kg 99 kg 101 kg Start of Stability Testing Sept Oct Dec. 0000
9 BIWG 98 SE drug substance Page 9 of Container Closure System A tight container is necessary according to the stress investigations with the drug substance. Therefore the samples were packed in 500 ml glass flasks with twist-off closure lined with polyethylene foil type Lupolene 3020 D. The same polyethylene foil is used in the stainless steel containers of the chemical production. Therefore a possible interaction can be investigated. The tight stainless steel container was simulated by the glass flask with the twist-off closure. 3.3 Test attributes In stability testing of BIWG 98 SE the attributes were investigated which are potentially susceptible to change during the course of storage and which are likely to influence quality, safety and/or efficacy. The following test attributes have been selected according to the results of the stress investigations with the drug substance: Appearance, odour, colour of solution, clarity of solution, melting behaviour, water content, degradation of BIWG 98 SE, assay of BIWG 98 SE, Assessment of container closure system.
10 BIWG 98 SE drug substance Page 10 of Analytical procedures The analytical procedures were stability indicating and completely validated according to the ICH Guidelines on validation. Specificity was demonstrated by separating the drug substance from 3 degradation products caused by stress investigation. Intermediate precision: Initial assay: Reporting threshold: RSD 0.65 %, single analysis was possible since RSD 0.65 % < 1 % 3-fold 0.05 % according to the ICH Guideline "Impurities in New Drug Substances", each impurity > 0.05 % (reporting threshold) can be quantitated. The test attributes, the analytical procedures and the release specifications are summarized in the: "Stability Testing Specifications BIWG 98 SE drug substance No. TSS 900-A-01/02". The validation procedures and the corresponding data are summarized in the: "Validation Report BIWG 98 SE drug substance No. VRS 900-A-01/V01". The analytical procedures were developed for the stability testing of BIWG 98 SE drug substance. The same analytical procedures were used for the investigation of the registration batches.
11 BIWG 98 SE drug substance Page 11 of Test attributes and Acceptance criteria Test attributes Appearance Odour Colour of the solution Clarity of the solution Melting behaviour Release acceptance criteria White to off-white substance Almost imperceptible Not more intensely coloured than reference solution Y 4 Not more opalescent than reference suspension II C (DSC at 3 K/min) Loss on drying Not more than 1 % Degradation of BIWG 98 SE Imp. I not more than 0.3 %, Imp. II not more than 0.3 %, any unspecified impurity (degradation) up to 0.1%, total impurities not more than 0.7 % Assay of BIWG 98 SE % Assessment of container closure system Appearance unchanged.
12 BIWG 98 SE drug substance Page 12 of Stability test protocols Accelerated and long-term testing according to the ICH Guideline Stability Testing of Drug Substances and Products Batch No. Container closure system Storage conditions [ C/%r.h.] Storage period Testing frequency [months] Stability Testing Specifications S96013 Polyethylene bag in twist-off glass flask 25 C/60% 0,3,6,9,12,18, (24, 36, 48, 60)¹ 40 C/75% 3,6 TSS 90-A-01/02 S96014 Polyethylene bag in twist-off glass flask 25 C/60% 0,3,6,9,12, (18, 24, 36, 48, 60)¹ 40 C/75% 3,6 TSS 90-A-01/02 S96015 Polyethylene bag in twist-off glass flask 25 C/60% 0,3,6,9,12, (18, 24, 36, 48, 60)¹ 40 C/75% 3,6 TSS 90-A-01/02 ¹On-going Stability testing Photostability testing according to the ICH Guideline Photostability Testing of New Drug Substances and Products For confirmatory studies samples should be exposed to light providing an overall illumination of not less than 1.2 million lux hours ( nm) and an integrated near ultraviolet energy of not less than 200 Wh/m² ( nm). The Suntest CPS (Atlas Corp.) is used. It is equipped with a Xenon lamp 22 hours at irradiance level of 250 W/m² =^ 22.5 W/m² with filter fulfilled the requirements.
13 BIWG 98 SE drug substance Page 13 of 30 Batch No. Container closure system Light source Storage time Stability Testing Specifications S96013 Open petri-dish Xenon lamp 22 hours TSS 90-A-01/02
14 BIWG 98 SE drug substance Page 14 of 30 4 Results and Evaluation 4.1 Graphic of test results Batch No.: S96013 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60% 40 C/75% Assay of BIWG 98 SE % 25 /60% r.h. 101,5 Linear Regression Line 40 /75% r.h. 101,0 101,5 Linear Regression Line 100,5 101,0 100,0 100,5 Assay % 99,5 99,0 98,5 Assay % 100,0 99,5 99,0 98,0 97, storage time (month) 98,5 98,0 97, storage time (month)
15 BIWG 98 SE drug substance Page 15 of 30 Batch No.: S96014 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60% 40 C/75% Assay of BIWG 98 SE % 25 /60% r.h. 101,5 101,0 Linear Regression Line 101,5 40 /75% r.h. Linear Regression Line 100,5 101,0 100,0 100,5 Assay % 99,5 99,0 98,5 98,0 Assay % 100,0 99,5 99,0 98,5 98,0 97, storage time (month) 97, storage time (month)
16 BIWG 98 SE drug substance Page 16 of 30 Batch No.: S96015 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60% 40 C/75% Assay of BIWG 98 SE % 25 /60% r.h. 101,5 Linear Regression Line 40 /75% r.h. Linear Regression Line 101,0 101,5 100,5 101,0 100,0 100,5 Assay % 99,5 99,0 98,5 Assay % 100,0 99,5 99,0 98,5 98,0 98,0 97, storage time (month) 97, storage time (month)
17 BIWG 98 SE drug substance Page 17 of Test results Batch No.: S96013 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60% 40 C/75% Appearance White to off-white substance 0 White to off-white substance 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged 18 unchanged Odour Almost imperceptible 0 Almost imperceptible 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged 18 unchanged Colour of the solution Not more intensely coloured than reference solution Y 4 0 Y 5 - Y 4 3 Y 5 - Y 4 Y 5 - Y 4 6 Y 5 - Y 4 Y 5 - Y 4 9 Y 5 - Y 4 12 Y 5 - Y 4 18 Y 5 - Y 4
18 BIWG 98 SE drug substance Page 18 of 30 Batch No.: S96013 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60% 40 C/75% Clarity of the solution Not more opalescent than reference suspension II 0 < II 3 < II < II 6 < II < II 9 < II 12 < II 18 < II Melting behaviour C (DSC at 3 K/min) C C 268 C C 268 C C C C Water content Not more than 1 % % % 0.3 % % 0.3 % % % %
19 BIWG 98 SE drug substance Page 19 of 30 Batch No.: S96013 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60 % 40 C/75 % Impurities and degradation of BIWG 98 SE Imp. I not more than 0.3 %, Imp. II not more than 0.3 %, any unspecified impurity (degradation) up to 0.1%, total impurities not more than 0.7 % 0 Imp. I 0.3 %; Imp. II 0.2 %; 3 Imp. I 0.2 %; Imp. II 0.2 %; 6 Imp. I 0.3 %; Imp. II 0.2 %; 9 Imp. I 0.3 %; Imp. II 0.2 %; 12 Imp. I 0.2 %; Imp. II 0.3 %; 18 Imp. I 0.3 %; Imp. II 0.2 %; Imp. I 0.3 %; Imp. II 0.2 %; Imp. I 0.2 %; Imp. II 0.3 %; Assay of BIWG 98 SE % % % % % % % % %
20 BIWG 98 SE drug substance Page 20 of 30 Batch No.: S96013 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60 % 40 C/75 % Assessment of packaging material Appearance unchanged. 0 faultless 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged 18 unchanged
21 BIWG 98 SE drug substance Page 21 of 30 Batch No.: S96014 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60 % 40 C/75 % Appearance White to off-white substance 0 White to off-white substance 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged Odour Almost imperceptible 0 Almost imperceptible 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged Colour of the solution Not more intensely coloured than reference solution Y 4 0 Y 5 - Y 4 3 Y 5 - Y 4 Y 5 - Y 4 6 Y 5 - Y 4 Y 5 - Y 4 9 Y 5 - Y 4 12 Y 5 - Y 4
22 BIWG 98 SE drug substance Page 22 of 30 Batch No.: S96014 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60 % 40 C/75 % Clarity of the solution Not more opalescent than reference suspension II 0 < II 3 < II < II 6 < II < II 9 < II 12 < II Melting behaviour C (DSC at 3 K/min) C C 268 C C 268 C C C Water content Not more than 1 % % % 0.4 % % 0.3 % % %
23 BIWG 98 SE drug substance Page 23 of 30 Batch No.: S96014 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60 % 40 C/75 % Impurities and degradation of BIWG 98 SE Imp. I not more than 0.3 %, Imp. II not more than 0.3 %, any unspecified impurity (degradation) up to 0.1%, total impurities not more than 0.7 % 0 Imp. I 0.3 %; Imp. II 0.2 %; 3 Imp. I 0.2 %; Imp. II 0.2 %; 6 Imp. I 0.3 %; Imp. II 0.2 %; 9 Imp. I 0.3 %; Imp. II 0.2 %; 12 Imp. I 0.2 %; Imp. II 0.3 %; Imp. I 0.3 %; Imp. II 0.2 %; Imp. I 0.2 %; Imp. II 0.3 %; Assay of BIWG 98 SE % % % % % % % % Assessment of container closure system Appearance unchanged. 0 faultless 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged
24 BIWG 98 SE drug substance Page 24 of 30 Batch No.: S96015 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60 % 40 C/75 % Appearance White to off-white substance 0 White to off-white substance 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged Odour Almost imperceptible 0 Almost imperceptible 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged Colour of the solution Not more intensely coloured than reference solution Y 4 0 Y 5 - Y 4 3 Y 5 - Y 4 Y 5 - Y 4 6 Y 5 - Y 4 Y 5 - Y 4 9 Y 5 - Y 4 12 Y 5 - Y 4
25 BIWG 98 SE drug substance Page 25 of 30 Batch No.: S96015 Storage time Container closure system Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60 % 40 C/75 % Clarity of the solution Not more opalescent than reference suspension II 0 < II 3 < II < II 6 < II < II 9 < II 12 < II Melting behaviour C (DSC at 3 K/min) C C 268 C C 268 C C C Water content Not more than 1 % % % 0.3 % % 0.3 % % %
26 BIWG 98 SE drug substance Page 26 of 30 Batch No.: S96015 Storage time Container closure system: Storage conditions 500 ml glass flask with twist-off closure lined with polyethylene foil [months] 25 C/60 % 40 C/75 % Impurities and degradation of BIWG 98 SE Imp. I not more than 0.3 %, Imp. II not more than 0.3 %, any unspecified impurity (degradation) up to 0.1%, total impurities not more than 0.7 % 0 Imp. I 0.3 %; Imp. II 0.2 %; 3 Imp. I 0.2 %; Imp. II 0.2 %; 6 Imp. I 0.3 %; Imp. II 0.2 %; 9 Imp. I 0.3 %; Imp. II 0.2 %; 12 Imp. I 0.2 %; Imp. II 0.3 %; Imp. I 0.3 %; Imp. II 0.2 %; Imp. I 0.2 %; Imp. II 0.3 %; Assay of BIWG 98 SE % % % % % % % % Assessment of Container closure system Appearance unchanged. 0 faultless 3 unchanged unchanged 6 unchanged unchanged 9 unchanged 12 unchanged
27 BIWG 98 SE drug substance Page 27 of 30 Batch No.: S96013 Storage time Container closure system Storage conditions Open petri-dish [hours] Xenon lamp Appearance White to off-white substance 0 White to off-white substance 22 unchanged Colour of the solution Not more intensely coloured than reference solution Y 4 0 Y 5 - Y 4 22 Y 5 - Y 4 Clarity of the solution Not more opalescent than reference suspension II 0 < II 22 < II Impurities and degradation of BIWG 98 SE Imp. I not more than 0.3 %, Imp. II not more than 0.3 %, any unspecified impurity (degradation) up to 0.1%, total impurities not more than 0.7 % 0 Imp. I 0.3 %; Imp. II 0.2 %; 22 Imp. I 0.2 %; Imp. II 0.3 %; Assay of BIWG 98 SE % % %
28 BIWG 98 SE drug substance Page 28 of Evaluation The three registration batches packed in polyethylene bags in 500 ml glass flasks with twist-off closure were investigated. The samples had been stored up to 18 respectively 12 months at 25 C/60 % r.h. and up to 6 months at 40 C/75 % r.h.. The analytical procedures were stability indicating and completely validated Organoleptical properties: During the storage no change in appearance or odour took place Physico-chemical properties: During the storage at both conditions no change in colour of solution, clarity of solution, melting behaviour and loss on drying occurred Chemical properties: During the storage no fall in assay took place. No degradation > 0.05 % was detected. Two known impurities did not change. Since no decomposition or fall in assay took place, the statistical evaluation was deleted. This is underlined by the graphical presentation of the data of assay of BIWG 98 SE. These data scatter slightly Container closure system properties: No interaction was found with the polyethylene foil Photostability: The Photostability was investigated applying the Suntest CPS (Atlas Corp.). After 22 hours (Confirmatory Testing) no change in any test criteria took place. According to the results BIWG 98 SE is not light sensitive.
29 BIWG 98 SE drug substance Page 29 of 30 5 Conclusion The NCE BIWG 98 SE is a stable drug substance. The Accelerated and Long-Term Stability test results with the three registration batches confirmed fully the data of the Stress-testing with the drug substance. No change took place in the organoleptical, physico-chemical, chemical and container closure system properties. Due to the hygroscopicity a slight increase in loss on drying was indicated. The drug substance is not sensitive to light according to the Photostability investigation. The tested polyethylene foil can be used for storage and shipment. The drug substance must be stored in tight containers. Special precautions for handling during production are not required. A preliminary re-test period of 24 months can be derived from the primary and supportive data. the stability testing will be continued up to 60 months with the expectation to extend the re-test period up to 60 months. It means all stability data are within release specifications.
30 BIWG 98 SE drug substance Page 30 of 30 6 Statements Storage instructions: - Keep the container tightly closed - Store in a dry place In the EU and Japan no further storage instructions are necessary. USA: Store at 25 C, excursions permitted (15-30 C) During shipment 30 C can be exceeded (3 months 70 C have been investigated) 249
Stability Report. Stability profile of. BIWG 98 SE tablets 40 mg SR of 133. This stability report comprises 133 pages.
Stability Report Stability profile of BIWG 98 SE tablets 40 mg Number SR 2001-01-04-01 Date Page 00. 00. 0000 1 of 133 Responsible Company Successful Pharma KG Biberach This stability report comprises
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
More informationSTABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW
More informationPHOTOSTABILITY TESTING OF NEW ACTIVE SUBSTANCES AND MEDICINAL PRODUCTS *)
PHOTOSTABILITY TESTING OF NEW ACTIVE SUBSTANCES AND MEDICINAL PRODUCTS *) Guideline Title Photostability Testing of New Active Substances and Medicinal Products *) Legislative basis Directive 75/318/EEC
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 December 2003 CPMP/QWP/122/02, rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE
More informationInternational Journal of Generic Drugs
Photostability STABILITY TESTING in New Drug Products evaluating photostability is foremost for new chemical entities only - not in generic drugs, provided the container-closure protection is the same
More informationSTABILITY TESTING OF NEW DRUG
VICH GL5 (STABILITY 3) May 1999 For implementation at Step 7 STABILITY TESTING ESTING: PHOTOSTABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS Recommended for Implementation at
More informationGUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationFOOD AND DRUGS AUTHORITY
G H A N A FOOD AND DRUGS AUTHORITY GUIDELINES FOR STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS AND FINISHED PHARMACEUTICAL PRODUCTS Document No: FDA/DRI/DER/GL-STP/2013/07 Date of First Adoption:
More informationThe GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G
The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G (1) INTRODUCTION The following guideline defines the stability data package for a drug
More informationGUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA
GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001 Republic of South Africa Tel. (**27
More informationSTABILITY: STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES (REVISION)
VICH GL3(R) (QUALITY) January 2007 Revision at Step 9 For Implementation at Step 7 STABILITY: STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES (REVISION) Recommended for Adoption at Step 7 of the VICH
More informationProposals for the Guideline on Classification of Variations. Only those variations applicable to the active substance are listed.
December 2008 Proposals for the Guideline on Classification of Variations Only those variations applicable to the active substance are listed. A variation which is not an extension and whose classification
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationManual 055 Commercial Stability Testing For Formulated Products. This procedure applies to all drug products. The procedure covers:
1 Purpose Manual 055 Commercial Stability Testing For Formulated Products The intent of this procedure is to provide to manufacturing and primary packaging sites the principles of a stability program.
More informationDEPARTMENT OF AGRICULTURE, FORESTRY & FISHERIES STABILITY
DEPARTMENT OF AGRICULTURE, FORESTRY & FISHERIES STABILITY This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of Stock Remedies. It represents
More informationDraft regional guidelines on stability testing of active substances and pharmaceutical products
Regional Committee for the EM/RC53/12 Eastern Mediterranean August 2006 Fifty-third Session Original: Arabic Agenda item 17 Draft regional guidelines on stability testing of active substances and pharmaceutical
More informationAnnex 10. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. Introduction and background
Annex 10 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products Introduction and background The guidance on Stability testing of active pharmaceutical ingredients and
More informationVICH Topic GL3. Step 7 (after revision at step 9) GUIDELINE ON STABILITY: STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/899/99-Rev.1 VICH Topic GL3 Step 7 (after revision at step 9) GUIDELINE ON STABILITY: STABILITY
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS
Association of South East Asian Nations (ASEAN) ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS Disclaimer: This document is provided for information purpose only and subject
More informationASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT. Version 4.0. Update revision : May Document Control
ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT Version 4.0 Update revision : May 2012 Document Control Version Date 1.0 July 2004 (8 th ACSQ PPWG Meeting; Bangkok) 2.0 February 2005 (9 th ACSQ PPWG
More informationVariation Regulations (EU)
Variation Regulations (EU) Headlines of the Update APIC c view Hilde Vanneste APIC Task Force leader Hilde.Vanneste@its.jnj.com 1 Content Scope of regulation: Type of procedures and hence 2 strands Current
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group Version Description of Change Author Effective Date v 1.0 Original publication ASMF/DMF WG May 26, 2015 v 1.1 Watermark added ASMF/DMF
More informationEVALUATION FOR STABILITY DATA
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION FOR STABILITY DATA Q1E Recommended for
More informationImpurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
More informationGUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION
ON ANALYTICAL METHOD VALIDATION HSA September 2004 Reproduction prohibited for commercial purposes. Reproduction for internal use is authorised, provided the source is acknowledged. MQA Dir: DISK1\GUIDE-MQA-012A-004.doc
More informationASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT
ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT Update revision : 22 February 2005. 9 th ACCSQ-PPWG Meeting, Philippines, 21-24 Feb 2005 LIST OF CONTENTS 1. INTRODUCTION 1 2. OBJECTIVES 1 3. SCOPES
More informationCase study 2: Parenteral Drug Product
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Purpose of Case Study 2: The following case study provides one example of a summary of an elemental impurities risk
More informationNOTICE Our file number:
September 25, 2003 NOTICE Our file number: 03-118437-914 Adoption of ICH 1 Guidance: - This guidance document is a revised version of the ICH Q1A(R) guidance document and defines the stability data package
More informationHEALTH DEPARTMENT. On the margin, a seal bearing the national symbol and the words United Mexican States Health Department.
Wednesday, January 4, 2006 OFFICIAL GAZETTE (Second Section) 1 HEALTH DEPARTMENT Official Mexican Standard NOM-073-SSA1-2005, Stability of Drugs and Medicine (modifies the NOM-073-SSA1-1993, Stability
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More informationGPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationGuidance for Industry Q3B(R2) Impurities in New Drug Products
Guidance for Industry Q3B(R2) Impurities in New Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationVICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus
More informationMODULE 2.3 QUALITY OVERALL SUMMARY PRODUCT DOSSIER (QOS PD)
MODULE 2.3 QUALITY OVERALL SUMMARY PRODUCT DOSSIER () INTRODUCTION The introduction should include proprietary name, non-proprietary name or common name of the drug substance, company name, dosage form(s),
More informationWorkshop Summaries. Discussions of the Global Stability Workshop are summarized for the following topics:
Workshop Summaries Discussions of the Global Stability Workshop are summarized for the following topics: QbD and Stability Program Dr. Alasandro Setting Specifications Dr. Gentry Challenges of Different
More informationMedicines Control Authority of Zimbabwe
EFV... QUALITY INFORMATION SUMMARY (QIS) FOREWORD The Quality Information Summary (QIS) template should be completed to provide a condensed summary of the key quality information for product dossiers (PDs)
More informationMINISTRY OF HEALTH AND SOCIAL SERVICES
MINISTRY OF HEALTH AND SOCIAL SERVICES NAMIBIA MEDICINES REGULATORY COUNCIL POST REGISTRATION AMENDMENT GUIDELINES These guidelines are meant to provide assistance to industry and health care professionals
More informationOutline. Opportunities Overview of ASAP Areas of Application ASAP Proposal to Regulators Summary
Outline Opportunities Overview of ASAP Areas of Application ASAP Proposal to Regulators Summary Opportunities n Provide cost benefits and possible alternate methods for demonstrating product stability
More informationG/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products.
G/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products. The Health Minister of Malaysia, as conferred by subregulation 1(2) of the Control
More informationUnderstanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation
Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation Ying Verdi IVT LAB WEEK EUROPE June 2017 Partners in Health Since 1919 Regulatory View of Method
More informationHow to ensure the Stability of Products in Clinical Trials an Industry Perspective. Volker Schnaible
How to ensure the Stability of Products in Clinical Trials an Industry Perspective Volker Schnaible Outline Why do we need stable development products? How to ensure stability How to use stability data
More informationExperience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014
Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A
More information2.3.S.2.5. Process Validation and/or Evaluation
2.3.S.2.5. Process Validation and/or Evaluation 12. What process validation and/or evaluation information is provided, if any? If the validation has been performed, summarized information regarding the
More informationVALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996
More informationChapter -1. Importance of Stability Indicating Analytical Methods for Analyzing Organic Impurities in Active Pharmaceutical Ingredients
Chapter -1 Importance of Stability Indicating Analytical Methods for Analyzing Organic Impurities in Active Pharmaceutical Ingredients 1.1 Introduction and importance of stability indicating analytical
More informationICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE
More informationNew Drug Product Impurities
Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint
More informationVICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/837/99-Rev.1 VICH Topic GL10 Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN
More informationWHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS
23 April 2008 Quality Assurance Programme Quality Assurance and Safety: Medicines (QSM) Department of Medicines Policy and Standards (PSM) World Health Organization CH-1211 Geneva 27 Switzerland WHO DRAFT
More informationPharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148
Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP
More informationStatistical Evaluation Of Stability Data
Reprinted from FDA s website by #219 GUIDANCE FOR INDUSTRY Statistical Evaluation Of Stability Data VICH GL51 DRAFT GUIDANCE This guidance document is being distributed for comment purposes only Submit
More informationVICH GL51: Quality: statistical evaluation of stability data
1 2 3 12 December 2011 EMA/CVMP/VICH/858875/2011 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 VICH GL51: Quality: statistical evaluation of stability data Draft Draft agreed by VICH Steering
More informationMedicine Variations Guideline
Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE- GENERAL Health systems and products Medicinal products quality, safety and efficacy 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal
More informationMedicines Variations Guideline
Medicines Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 27/08/2014 Version 1.1 Chief of Pharmaceutical Product Regulation: Dr / Roaya Al Abbasi Date: NHRA CEO Approval:
More informationRegulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017
Regulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017 Hugo Hamel, Senior Biologist/Evaluator, BGTD Overview of the Post-NOC Changes
More informationINTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
International Journal of Institutional Pharmacy and Life Sciences 5(1): January-February 2015 INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES Pharmaceutical Sciences Review Article!!!
More informationValidation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.
Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. 1 Analytical Method Validation: 1..1 Philosophy: Method validation is
More informationPreparing the CMC section of IMPD for biological/biotechnology derived substances
Preparing the CMC section of IMPD for biological/biotechnology derived substances Your Logo Dr. Una Moore Health Products Regulatory Authority, Ireland Presented by Una Moore on 16 th April 2014. Health
More informationGUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE IA AND TYPE IB NOTIFICATIONS July 2003
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Final Revision 0 NOTICE TO
More informationInvestigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd
Investigating OOS for Finished Product on the Stability Program Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd Overview 1. Requirements of the commercial stability program 2. Out of Specification
More informationá1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
More informationAPI Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016
API Testing Requirements to Support the EI Risk Assessment Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016 Agenda Background Review of ICH Q3D Risk Assessment Principles
More informationAdopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016
1 September 2017 EMA/CHMP/ICH/809509/2016 Committee for Human Medicinal Products ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological
More informationCurrent version 13 October 2016
Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order
More informationStability of Biological Products
Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth
More informationSESSION 11 Stability Data Evaluate, Set Specifications and Prepare Reports
SESSION 11 Stability Data Evaluate, Set Specifications and Prepare Reports Dan Willingmyre, Neha Frantz, Philip Pue-Gilchrist, Donnie Pulliam, Ketan Shah, and Brian K Nunnally Agenda Introduction Inputs
More informationFurther Stability Considerations
Further Stability Considerations Radhika Rajagopalan, Ph.D., Team Leader Chemistry Division 2 Office of Generic Drugs, FDA FDA-GPhA Workshop June 4, 2013 1 Agenda Common considerations Q1D Bracketing and
More informationParadigm Shift in Comparability Assessment:
Paradigm Shift in Comparability Assessment: How Quality by Design (QbD) and Process Analytical Technology (PAT) can improve Structure-Activity Relationship (SAR) evaluation and its relevance to comparability
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationA STANDARD PROTOCOL for DERIVING and ASSESSMENT of STABILITY. Part 3 Oral Liquid Medicines (Solutions, Emulsions, Suspensions and Syrups)
A STANDARD PROTOCOL for DERIVING and ASSESSMENT of STABILITY Part 3 Oral Liquid Medicines (Solutions, Emulsions, Suspensions and Syrups) EDITION 1 August 2014 NHS Pharmaceutical Quality Assurance Committee
More informationQuestions and answers on the 'Guideline on the limits of genotoxic impurities'
23 September 2010 EMA/CHMP/SWP/431994/2007 Rev. 3 Committee for Medicinal Products for Human Use (CHMP) Safety Working Party (SWP) Questions and answers on the 'Guideline on the limits of genotoxic impurities'
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationEU Regulatory Perspective and Expectations. Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden
EU Regulatory Perspective and Expectations Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden Disclaimer EU regulators still have to build up an experience of applications based
More informationChemical Aspects of Stability Evaluation
Chemical Aspects of Stability Evaluation 8 steps to generating stability data which speaks for itself Alan Doughty Chief Chemist Pty Ltd Aim of a stability trial Obtain data which allows a definitive conclusion
More informationBlister development today still daily business? Markus Schönfeld 21. Sept 2015
Blister development today still daily business? Markus Schönfeld 21. Sept 2015 Are you familar with these statements? We develop and manufacture blisters since many decades Alumnium blisters are water
More informationCOMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS
COMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS Additional guidance for manufacturers This note identifies the most common quality related deficiencies in recently assessed dossiers
More informationGuideline on the chemistry of active substances for veterinary medicinal products
9 November 2017 EMA/CVMP/QWP/707366/2017 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on the chemistry of active substances for veterinary medicinal products Draft agreed by Quality
More informationApplication note. Guideline for validation of analytical methods using Cedex Bio, Cedex Bio HT, and Cedex HiRes Analyzers.
Application note Guideline for validation of analytical methods using Cedex Bio, Cedex Bio HT, and Cedex HiRes Analyzers April 216 Doerthe Druhmann, Sabrina Schuette, Dr. Dirk Ponsel Pharma Biotech, Penzberg,
More informationSAFETY DATA SHEET TRIPLEWAX SHAMPOO
Report Date : 17/03/2015 1 / 7 Revision Date 21/03/2014 Revision 28 Supersedes date 18/02/2014 V27 SAFETY DATA SHEET SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1.
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
20 September 2017 EMA/CHMP/QWP/546045/2017 Overview of comments received on 'Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal
More informationGUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET
GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda
More informationApproval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D.
Approval Review of Generic Drugs Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D. Outline of Presentation Introduction Approval Review of Generic Drugs Equivalency review Conformity audit Conclusion
More informationPerspectives on Method Validation: Importance of Adequate Method Validation
Perspectives on Method Validation: Importance of Adequate Method Validation Heather Bridwell, Vikas Dhingra, Daniel Peckman, Jennifer Roark and Thomas Lehman The appropriate validation of analytical methods
More informationBEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development
- ASPECTS OF COMPOUNDING PRODUCT DESIGN Reinout C.A. Schellekens, PharmD, RHPh, QP Head Clinical Drug Production and Development Department of Hospital and Clinical Pharmacy University Medical Center Groningen,
More informationReplacing Analytical Methods for Release and Stability Testing A Regulatory Perspective
Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Presentation at The IVT s 12 th Annual Analytical Procedure and Method Validation Conference Dec 12, 2016 Lokesh
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationEN Official Journal of the European Union. (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1084/2003.
L 159/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1084/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal
More informationGuideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials
1 2 3 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the Requirements for Quality Documentation Concerning Biological Investigational
More informationINTERNAL STANDARD. Inorganic Pigments TYTANPOL TITANIUM WHITE
Grupa Azoty Zakłady Chemiczne Police S.A. INTERNAL STANDARD Inorganic Pigments TYTANPOL TITANIUM WHITE ZN ZChP 435:2016 replaces ZN ZChP 435:2007 Date: prepared on revised on 02.08.2016-1. SUBJECT OF THE
More informationSPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune
SPECIFIC MONOGRAPHS A Guide Through The Different Sections Claude Coune Claude Coune, EDQM, Council of Europe, All rights reserved, 2010 1 Contents of the European Pharmacopoeia: nearly 2100 monographs
More information10. Validated Normal Phase HPLC Method for the Determination. Fulvestrant is primarily used in the treatment of hormone receptor
229 10. Validated Normal Phase HPLC Method for the Determination of Fulvestrant in Pharmaceutical Dosage Forms 10.1 Introduction Fulvestrant is primarily used in the treatment of hormone receptor positive
More information